

Human chorionic gonadotrophin as an indicator of persistent gestational trophoblastic neoplasia

Soheila Aminimoghaddam¹, Fariba Yarandi², Forough Nejadslami³
Farrokh Taftachi⁴, Fereshteh Noor bakhsh⁵, Fatemeh Mahmoudzadeh⁶

Received: 15 June 2013

Accepted: 25 Dec 2013

Published: 11 June 2014

Abstract

Background: Gestational trophoblastic neoplasia (GTN) disease is excessive and inappropriate proliferation of trophoblast after termination of the pregnancy. Many attempts have been made to improve follow-up procedures, but no studies have evaluated Human Chorionic Gonadotrophin (HCG) as a post treatment indicator. Thus we aimed to know β -HCG variability in post treatment pregnancies.

Methods: 40 Molar affected pregnancies were followed post-surgical treatment by serum β -HCG level in a tertiary level hospital. All subjects were treated by evacuation and followed by β -HCG every week for three weeks, then every month for six months.

Results: 30 women were normal (group I) and 10 (group II) diagnosed as GTN cases. Serum β -HCG which obtained serially shown significant differences between two groups ($p=0.001$). The quantity of β -HCG/week had significantly higher level than normal females ($p<0.001$)

Conclusion: Our results suggested that β -HCG serum level could be used as a strong indicator for identifying affected patients at early stage.

Keywords: Gestational trophoblastic neoplasia, Molar pregnancy, β -HCG, Chemotherapy.

Cite this article as: Aminimoghaddam S, Yarandi F, Nejadslami F, Taftachi F, Noor bakhsh F, Mahmoudzadeh F. Human chorionic gonadotrophin as an indicator of persistent gestational trophoblastic neoplasia. *Med J Islam Repub Iran* 2014 (11 June). Vol. 28:44.

Introduction

Gestational trophoblastic neoplasia (GTN) is an excessive and inappropriate proliferation of trophoblast after the end of pregnancy that comprised a spectrum of pregnancy-related disorders. Initial treatment involves uterine evacuation, with a histopathological diagnosis (1). There are significant regional and racial differences in the incidence of GTN worldwide. It is a rare but important pregnancy-related disorder with an incidence of 1 in 400 in Asia and Latin America with higher rate in western countries (1, 2). The GTN is one of the most curable malignancies. The intrinsic

sensitivity of the tumor to certain antineoplastic agents, in particular sensitive assays for human chorionic gonadotropin, has made it detectable and capable of being efficiently followed-up (2). The GTN requires chemotherapy, surgery or a combined treatment modality (3). Chemotherapy is the main modality of treatment for patients with GTN.

The cure rate in patients with low-risk GTN is approximately 100% and is estimated to exceed 80% in patients at high-risk (4,5). Surgical treatment such as a hysterectomy is rarely needed. However, in some countries, the incidence of hysterec-

1. Assistant Professor of Obstetrics and Gynecology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran. dr_aminimoghaddam@yahoo.com

2. (Corresponding author) Associate Professor of Obstetrics and Gynecology, Tehran University of Medical Sciences, Tehran, Iran. yarandi_f@yahoo.com

3. Resident of Obstetrics and Gynecology, Iran University of Medical Sciences, Tehran, Iran.

4. Assistant Professor of Legal Medicine, Tehran University of Medical Sciences, Tehran, Iran. ftaftachi@yahoo.com

5. Resident of Obstetrics and Gynecology, Iran University of Medical Sciences, Tehran, Iran.

6. Medical student of Mazandaran University of Medical Sciences, Sari, Iran.

tomy has been estimated to be up to 35% in all cases of GTN (6). Post-surgical treatment follow up of patients is a main goal of new medicine. Many attempts have been made to improve follow-up procedures, but there are no studies that have evaluated Human Chorionic Gonadotrophin (HCG) as a post treatment indicator. Therefore we aimed to know β -HCG variability in post treatment pregnancies.

Method

Subjects

In this Cross-sectional study, all patients with molar affected pregnancies during year 2012, referred to Firoozgar Hospital obstetrics and gynecology. We followed consecutive 40 molar affected pregnancies post-surgical treatment by serum β -HCG level in patients. All patients with invasive molar, a history of prophylactic chemotherapy and also metastatic case were excluded. All subjects were treated by uterine evacuation and followed by β -HCG every week for three weeks, then every month for six months. In addition demographic data, gestational and abortion past history were used in this study.

The women were divided into two groups based on GTN involvement after three weeks based on HCG levels. All data included serial β -HCG which compared together. That was aimed to know GTN effects on variation of serum β -HCG differences at exact times in post treatment period. The β -hCG was measured by a solid-phase, twosite immunoradiometric assay (ELSA F- β HCG; CIS Ltd., Gif-sur-yvette Cedex, France) maximum of 2 hours post antecubital phlebotomy.

Statistical Analysis

Mean, median, range, standard deviation (SD), frequency and frequency percentage were determined using statistical software SPSS (Statistical Package for the Social Sciences, version 19.0, SPSS Inc, Chicago, Illinois, USA), and using descriptive analyses. For comparison of the averages between study groups, independent T test was

used after the normal distribution of data tested to determine whether it followed by 1-sample KS; and Chi square statistical test used for the comparison of qualitative ratios. Generalized linear Model (GLM) was utilized to appear significant differences in time-HCG between two groups. In all tests, significance level was considered as two tails with p value less than 0.05.

Results

30 women were normal (group I) and 10 other (group II) were detected as GTN cases.

The mean age of patients was 28.4 ± 4.6 years in group I (with no evidences of GTN), and 30.2 ± 4.7 years in group II (affected by GTN), with no significant difference ($p = 0.32$).

There were infertility problems among 3 and 1 patients in Group I and II, respectively ($p = 0.34$), with the Follow-up time of 25 to 27 weeks.

Abortion history was found in one, from GTN group, which did not differ significantly with the other group.

Gravity with a mean of 2.1 ± 0.6 and 2.2 ± 0.6 in Group I and II, respectively, also without significance difference ($p=0.35$).

The Serum β -HCG obtained serially shown significant differences between two groups ($p=0.001$), but its amounts had decreasing pattern in normal group rather than the GTN affected cases. However toward the end of study this pattern was reversed, particularly between 25-27th weeks.

The GLM model demonstrated that the amount of β -HCG/week had significantly higher level than normal females ($p<0.001$) (Fig.1). Combined diagrams are also shown in the results.

Discussion

There is no single test currently available that exactly differentiates continuing non-complicated from GTN in post molar treated cases. Ultrasound scanning and β -HCG are probably the best single diagnostic and prognostic tests available in threatened uterine evacuation. Despite of importance




Fig. 1. The β -HCG/week results for the normal and case group.

of β -HCG level in follow up there was no attempt to evaluate post op amounts of serum β -HCG in these patients.

The normal range of free β -HCG has been debated (7-13). Kang et al (8) suggested that the range of free β -HCG is narrow and constant throughout pregnancy. McGrath et al. (10) suggested high early concentrations which declined prior to the HCG peak.

Rangwala et al (12) and Thomas et al. (14) suggested that free β -HCG concentrations increase rapidly, reaching maximum values at 8-9 weeks of gestation and then declining gradually during the following 11-12 weeks; however, the values remained very low in comparison with those of HCG. Alazzam et al (13) found a significant free J-HCG peak in the third month of gestation.

Nevertheless, the same studies exhibited considerably more agreement on the concentrations of HCG, which show wide variations at different stages of pregnancy in the same individuals and also among women with pregnancies of the same gestational age. The HCG concentrations also show considerable overlap with abnormally low and high values, which makes the interpretation of any results difficult, especially at the time of the HCG peak at 1-12 weeks of gestation. In addition, the half-life of HCG is probably long. It has been reported to be between 12 h (11-15).

Gestational trophoblastic neoplasia is

highly responsive to chemotherapy and prognosis is excellent following treatment, especially in low-risk patients. Some previous studies have examined the link between hCG levels and the likelihood of complete treatment of molar pregnancy without significant difference in the median hCG values when comparing the group that completed low-risk treatment with those that required a change of treatment.

There was no evidence to clarify role of β -HCG in diagnosis of post molar complications. We found that β -HCG decreased more rapidly in non-affected women, however at fewer amounts this fluctuated reversely. Indeed β -HCG/week ratio differed significantly between the groups, reflects that normal patient's hormone fell more rapid than affected people.

Based on our data we resulted that there was a significant differences of β -HCG amount between two groups of post molar women, one which treated completely and other who switched to the GTN. In both groups post molar β -HCG curve decreased however this rate was significantly faster in cured women. It means that post molar β -HCG curve could acts as a suitable guide to show GTN and differed it from healthy cases, and also useful for post molar follow up.

Our study had weak points and lack some dimensions. Hyperglycosylated HCG is another isomer of β -HCG that could appear

brightly as a guide factor to detect post molar situation in complicated pregnancies. This type of β -HCG may appear some differences and plays an axis role to differentiated treated post molar pregnancies from GTN.

Conclusions

For first time in this profile we tried to understand variability of β -HCG concentrations based on post molar complications. Our results suggested that β -HCG serum level could be used as a meaningful indicator to distinguish affected patients at early stage of the treatment.

In summary, our data suggests that it is reasonable to rely on post treatment β -HCG to distinguish complicated molar pregnancy from completely treated one.

References

1. Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C. Epidemiology and aetiology of gestational trophoblastic diseases. *Lancet Oncol* 2003; 4:670-8.
2. Ghaemmaghami F, Ashraf-Ganjooie T. Gestational trophoblastic neoplasia. *Asia-Pacific J Clin Oncol* 2006; 2:9-21.
3. Ngan HY. The practicability of FIGO 2000 staging for gestational trophoblastic neoplasia. *Int J Gynecol Cancer* 2004; 14:202-5.
4. Newlands ES. The management of recurrent and drug-resistant gestational trophoblastic neoplasia (GTN). *Best Pract Res Clin Obstet Gynaecol* 2003; 17:905-23.
5. Ghaemmaghami F, Behtash N, Soleimani K, Hanjani P. Management of patients with metastatic gestational trophoblastic tumor. *Gynecol Oncol* 2004; 94:187-90.
6. El-Lamie IK, Shehata NA, Abou-Loz SK, Eilamie KI. Experience of the Gynecologic Oncology Unit at Ain Shams University in the treatment of gestational trophoblastic tumors. *Int J Gynecol Cancer* 2000; 10:488-96.
7. Agarwal R, Harding V, Short D, Fisher RA, Sebire NJ, Harvey R, Patel D, Savage PM, Lim AK, Seckl MJ. Uterine artery pulsatility index: a predictor of methotrexate resistance in gestational trophoblastic neoplasia. *Br J Cancer*. 2012; 28: 65.
8. Kang WD, Choi HS, Kim SM. Prediction of persistent gestational trophoblastic neoplasia: the role of hCG level and ratio in 2 weeks after evacuation of complete mole. *Gynecol Oncol*. 2012; 124(2):250-3.
9. Kim BW, Cho H, Kim H, Nam EJ, Kim SW, Kim S, Kim YT, Kim JH. Human chorionic gonadotrophin regression rate as a predictive factor of postmolar gestational trophoblastic neoplasm in high-risk hydatidiform mole: a case-control study. *Eur J Obstet Gynecol Reprod Biol*. 2012; 160(1):100-5.
10. McGrath S, Short D, Harvey R, Schmid P, Savage PM, Seckl MJ. The management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1). *Br J Cancer*. 2010 2; 102(5):810-4.
11. Ng TY, Wong LC. Diagnosis and management of gestational trophoblastic neoplasia. *Best Pract Res Clin Obstet Gynaecol*. 2003; 17(6):893-903.
12. Rangwala TH, Badawi F. A profile of cases of gestational trophoblastic neoplasia at a large tertiary centre in dubai. *ISRN Obstet Gynecol*. 2011; 2011:453190
13. Alazzam M, Young T, Coleman R, Hancock B, Drew D, Wilson P, Tidy J. Predicting gestational trophoblastic neoplasia (GTN): is urine hCG the answer? *Gynecol Oncol*. 2011; 122(3):595-9
14. Thomas, C.M.G., Reijnders, F.J.L., Segers, M.F.G., Doesburg, W.H. and Rolland, R. Human choriongonadotropin (hCG): comparison between determinations of intact bCG, free hCG b-suhranit, and 'total' bCG + b in serum during the first half of high-risk pregnancy. *Clin. Chem*. 1990; 36: 651-655.
15. Fatemeh Ghaemmaghami, Tahereh Ashraf-Ganjooie. Gestational trophoblastic neoplasia. *Asia-Pacific Journal of Clinical Oncology*: 2006; 2(1): 9–21.